Investigational drug · Phase 2
QLS7305
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "QLS7305"
First trial start
2026
Aug 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLS7305", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgAN - IgA Nephropathy
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
- C3 Glomerulopathy (C3G)
- Primary Membranous Nephropathy
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "QLS7305" as an intervention, largest first.
- Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)Not yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07730632 · 60 participants (planned) · Start Aug 10, 2026 · Primary completion Aug 10, 2028
Drug: QLS7305 Injection · For: IgAN - IgA Nephropathy; Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN); C3 Glomerulopathy (C3G) and 1 more
Sites: Beijing, China
- A Phase I Trial of Subcutaneous QLS7305 in Healthy AdultsNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07313150 · 60 participants (planned) · Start Jan 2026 · Primary completion Dec 2027
Drug: QLS7305 Injection; Placebo Control · For: Healthy Volunteers - Male and Female
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.